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in vasodilatation and provides protection against hypoxiainduced vascular damage through a promotion of angiogenesis, suggesting that NOX4 may play a vasculoprotective role. 9, 10 However, studies in a stroke model demonstrated a deleterious role for NOX4 because Nox4 −/− animals showed reduced stroke area in association with attenuated oxidative stress, reduced blood-brain barrier leakage and neuronal apoptosis. 11 Furthermore, in the heart, using the same model of cardiac hypertrophy and cardiomyocyte injury, contrasting effects of NOX4 have been reported, which were either deleterious or protective. [12] [13] [14] [15] Accelerated plaque formation is observed in the context of diabetes mellitus, with atherosclerotic lesions often being more inflammatory and fibrotic. Furthermore, diabetic plaques undergo extensive vascular remodeling leading to plaque expansion and remodeling. 16, 17 The superoxide-generating type 1 NADPH oxidase (NOX1) has been shown to be induced and play a pivotal role in early phases of mouse models of atherosclerosis and in the context of diabetes mellitus. Here, the effect of long-term NOX4 and NOX1 deletion were investigated in the context of diabetes mellitus.
Surprisingly, we observed a reduced Nox4 gene expression in plaques of patients with cardiovascular events as well as in diabetic patients. We therefore examined the relationship of Nox4 versus Nox1 expression with plaque development in an established murine model of accelerated plaque formation, the streptozotocin-induced diabetic ApoE −/− mouse. 18 The data are of interest not only with respect to the qualitative role of reactive oxygen species (ROS) in atherosclerosis but also for the possible safety profile of NOX1/4 inhibiting drugs currently in clinical development for cardiovascular and other indications.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Human Atherosclerotic Plaque RT-PCR
Total RNA was extracted from diabetic and nondiabetic carotid endarterectomy specimens obtained from surgery (BioBank, Baker IDI Heart and Diabetes Institute and Department of Surgery, Alfred Hospital, Melbourne) homogenization in TRIzol reagent (Invitrogen Australia, Mt Waverly, Victoria, Australia). DNA-free RNA was reverse transcribed to generate cDNA using the Superscript First Strand Synthesis System (Life Technologies BRL, Grand Island, NY) as previously described. 3 Total RNA was also extracted from carotid endarterectomy specimens obtained from surgery (Department of Surgery, Maasland Hospital Sittard, Sittard, The Netherlands). 19 Samples were individually hybridized to Illumina Human Sentrix-8 V2.0 BeadChip (Illumina Inc, San Diego, CA). 20, 21 The adjusted P values presented in the results are corrected according to the Benjamini and Hochberg False Detection Rate method.
Animal Model
All animal experiments conducted in accordance to the principals and guidelines devised by the Alfred Medical Research and Education PrecinctAnimal Ethics Committee under the guidelines laid down by the National Health and Medical Research Council of Australia. Six-week-old male mice were rendered diabetic by streptozotocin (Sigma-Aldich, St. Louis, MO) as previously described. 3, 11, 22 After 20 weeks, the animals were anesthetized by intraperitoneal injection of sodium pentobarbitone (100 mg/kg body weight; Euthatal, SigmaAldrich, Castle Hill, NSW, Australia).
Atherosclerotic Plaque Area Quantification
Assessment of plaque area was undertaken using en face analysis as previously described. 23 
Cell Culture
Human arterial endothelial cells (HAECs) were obtained from Clonetics (Lonza) and grown in endothelial growth media-2 at normal (5 mmol/L) glucose. Cells used for RT-PCR were plated in media supplemented in either normal (5 mmol/L) or high (25 mmol/L) glucose for 48 hours before being harvested for RNA or protein isolation. Cells used for ROS analysis were plated in 96 well plates in either normal or high glucose for 24 hours before being used for ROS analysis.
Knockdown and Overexpression of Nox4 In Vitro
The knockdown of Nox4 was performed in HAECs using MISSION shRNA expressing lentivirus vectors as described previously. 24 The knockdown efficiency in the cells was verified by RT-PCR, and it was >90% for Nox4. Stable overexpression of Nox4 was performed in HAECs using as previously described 25 and overexpression was confirmed by RT-PCR.
Knockdown of Nox2 In Vitro
The knockdown of Nox2 was performed in HAECs using Lipofectamine RNAiMAX reagent with either scramble siRNA or siRNA targeted to Nox2 (NM_000397.3). Knockdown efficiency was verified by RT-PCR, and it was >50% for Nox2.
Measurement of ROS In Vitro
ROS production in HAEC (±glucose) was measured by Amplex Red (Molecular Probes, Eugene, OR), L-012 (Wako Chemicals, Richmond, VA), and Nitrotyrosine ELISA (Abcam, Cambridge, AM).
26,27
Quantitative RT-PCR Total aortic RNA was extracted after homogenization (Polytron PT-MR2100; Kinematica, Littau/Lucerne, Switzerland) of whole aorta in TRIzol reagent (Invitrogen Australia). DNA-free RNA was reverse transcribed to generate cDNA using the Superscript First Strand Synthesis System (life Technologies BRL, Grand Island, NY) as previously described. 
Histological Stains, Immunohistochemistry, and immunofluorescence
Paraffin sections (4 µmol/L) of aorta were used for histological stains (Masson Tirchome and Picro-Sirius Red) as previously described. 28, 29 Immunohistochemistry was also performed on paraffin sections of aorta for nitrotyrosine ( 
Activity Assays
Aortic superoxide generation was evaluated in frozen aortic sections with the oxidative fluorescent dye dihydroethidium as described previously. 32 Hydrogen peroxide (H 2 O 2 ) generation was measured in 10 to 15 mm segments of aortas by Amplex Red using a commercial kit following manufacturer's instructions (Molecular Probes, Eugene, OR). 3, 27 Nitrotyrosine concentrations were measured in whole aortic homogenates using a commercial kit following manufacturer's instructions (Abcam). Rac-1 activity was measured in cells grown under normal and high glucose conditions using a commercial kit following manufacturer's instructions (Cytoskeleton, Denver, CO).
Biomarkers
To measure circulating levels of monocyte chemotratic protein 1 (MCP-1), plasma samples were obtained from all experimental mice 1 week before experimental end and quickly frozen at −20°C. Plasma samples were sent to Aushion BioSystems (Aushion BioSystems, Billerica, MA) for analysis of MCP-1 concentrations using the Circa Immunoassay. Aortic MCP-1, tumor necrosis factor-α (TNFα), and interleukin (IL)-1β were measured in whole protein preparations as described previously 33 and measured using commercial kit's following manufacturer's instructions (R&D Systems, Minneapolis, MN).
Western Blot
Western blots of total aortic protein were performed as previously described targeting t-SMAD3 (rabbit monoclonal; OriGene, Rockville, MD; 1:500) and p-SMAD3 (rabbit monoclonal; Abcam; 1:250).
34,35

Statistical Analysis
Data were analyzed for normality using the Shipiro-Wilk test before being analyzed with either a t Test performed or a 1-way ANOVA or a 2-way ANOVA using SPSS Statistics version 20 (IBM) with an LSD post hoc test for multiple comparisons of the means, P<0.05 was considered statistically significant. All results are mean±SEM, unless otherwise specified.
Results
Nox4 Gene Expression Is Reduced in Plaques of Patients With Cardiovascular Events and in Diabetic Subjects Compared With Nondiabetic Subjects
Gene expression data using human carotid plaque material demonstrated reduced Nox4 expression in plaques removed from subjects with cardiovascular events compared with subjects without cardiovascular events ( Figure 1A ). In a separate cohort of nondiabetic and diabetic subjects, we similarly found a 65% reduction in Nox4 gene expression in plaques Figure 1 . Gene expression data in plaques from human subjects with cardiovascular events compared with those without cardiovascular events demonstrated reduced gene expression of Nox4 (A). In another cohort, diabetic subjects with cardiovascular disease demonstrated a significant reduction in the expression of Nox4 (65%) compared with nondiabetic subjects with cardiovascular disease (B). Nox1 and Nox4 isoform expression in diabetic and nondiabetic ApoE −/− mice after 10 weeks of diabetes mellitus and 20 weeks of diabetes mellitus (C and D). After 10 weeks of diabetes mellitus, Nox1 and Nox4 are significantly elevated in expression compared with control ApoE
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of diabetic subjects versus nondiabetic subjects ( Figure 1B ). The subject characteristics are summarized in Table II in the online-only Data Supplement.
Nox4 Expression Is Reduced in Advanced Mouse Atherosclerotic Plaques
We next measured Nox4 gene expression in aortic samples from diabetic and nondiabetic ApoE −/− mice, a mouse model of accelerated atherosclerosis. Gene expression of the Nox isoforms Nox1 and Nox4 were examined at 10 and 20 weeks after diabetes mellitus induction. After 10 weeks of diabetes mellitus that is characterized by early plaque development and fatty streaks, gene expression of both Nox4 and Nox1 was significantly elevated in aortas of diabetic ApoE −/− mice compared with control ApoE −/− mice ( Figure 1C and 1D) . After an additional 10 weeks of diabetes mellitus, at which time point more advanced plaques have developed, we observed a significant time-dependent decline in Nox4 expression in plaques (P<0.05, F=5.24), which was dependent on the diabetic status of the mouse (time and diabetes mellitus interaction, P<0.05, F=7.44, Figure 1C ). In contrast, although there was a modest decline in Nox1 gene expression, this was still significantly upregulated compared with ApoE −/− control mice ( Figure 1D ).
Deletion of Nox4 in Diabetes Mellitus Increases the Development of Atherosclerosis
On the basis of the surprising finding that Nox4 gene expression was reduced in more advanced vascular disease associated with plaque vulnerability, we embarked on delineating the role of NOX4 in a long-term model (20 (Figure 2A-2D) . Deletion of the NOX4 isoform in diabetes mellitus significantly further increased atherosclerotic plaque Figure 3F ). Dihydrothethidium immunofluorescence (for total oxidative capacity) and nitrotyrosine Dihydroethidium immunofluorescence demonstrated a significant elevation within the vasculature of both diabetic Nox4 and Nox1 WT mice. Deletion of Nox4 resulted in increased dihydroethidium staining, whereas deletion of the Nox1 resulted in a reduced dihydroethidium stain ( Figure 3G and 3H); immunopositive tyrosine nitration in the aortic wall and by ELISA was increased in diabetic WT mice and remained elevated in Nox4 −/− ( Figure 3A and 3B) but was Figure 3B-3D ). Thus, in this setting the nitrotyrosine biomarker may indicate interaction of NOX1-derived superoxide with NO to yield peroxynitrite, a potent nitrating species. However, we cannot exclude that upregulated NOX2/p47phox levels also contributed to this.
Nox4 Deficiency Increases Expression of Proinflammatory Markers and Aortic Macrophage Accumulation
With the identification of increased expression of Nox2, p47phox and sustained increased activity of dihydroethidium and nitrotyrosine accumulation within the aortic wall of diabetic Nox4 −/− ApoE −/− mice, we next examined inflammatory mechanisms that are promoted by oxidative stress.
There was a modest increase in circulating MCP-1 concentration in both diabetic Nox4 and Nox1 WT mice ( Figure 4A and 4D). Deletion of the NOX4 isoform in diabetes mellitus Figure 4B ). However, deletion of the NOX1 isoform significantly attenuated the diabetes mellitus-induced increase in MCP-1 concentration ( Figure 4E ). MCP-1 accumulation would be expected to increase adherence of immune cells to the vascular wall, particularly macrophages. Increased macrophage accumulation within the aortic wall was observed in both diabetic Nox4 and Nox1 WT mice ( Figure 4C and 4F). Deletion of the NOX4 isoform significantly further increased macrophage accumulation within the aortic wall ( Figure 4C ), whereas deletion of NOX1 significantly reduced macrophage accumulation ( Figure 4F ; Figure III in the onlineonly Data Supplement). We further examined proinflammatory factors involved in atherosclerosis, with a specific focus on those that have an upstream profibrotic role, including TNFα and IL-1β. 16 The diabetes mellitus-induced increase in aortic IL-1β gene expression was significantly attenuated in Nox1-deficient mice but was further increased in Nox4-deficient mice ( Figure IVA 
Nox4 Deficiency Increases Fibrillar Collagen Deposition Within Atherosclerotic Plaques in Association With Enhanced Transforming Growth Factor β-SMAD Signaling
Fibrosis is a critical step in the progression of atherosclerosis, through the establishment of plaque expansion and remodeling. 16 Diabetic Nox4
ApoE −/− mice showed significant elevations in the gene expression of the fibrillar collagens I ( Figure 5A ) and III ( Figure 5B ), but not collagen IVα3 ( Figure 5C ) in the aortic wall. Deletion of the NOX4 isoform in diabetes mellitus resulted in a significant further increase in the expression of collagens I and III ( Figure 5A and 5B), with a significant downregulation in the expression of collagen IVa3 ( Figure 5C ). In contrast, in diabetic Nox1 WT mice there was increased expression of collagens I ( Figure 5E ) and IVα3 ( Figure 5G ), but not collagen III ( Figure 5F ). Deletion of Nox1 in diabetes mellitus attenuated collagen I expression, with no change in the expression of collagens III and IVα3 ( Figure 5E-5G) . These results indicate that there is increased de novo formation and deposition of the newly formed fibrillar collagens, collagens I and III in diabetic Nox4-deleted mice, whereas the basement membrane collagen IV was reduced. Increased extracellular matrix accumulation in the plaques of diabetic Nox4 28 we demonstrated that diabetic Nox4-deficient mice showed increased collagen deposition within the plaques, which were predominantly lighter and newly formed fibrillar fibers including collagens I and III, and reduced accumulation The profibrotic growth factor transforming growth factor β (TGFβ) has been shown to be involved in extracellular matrix accumulation within atherosclerotic plaques and has been shown to be regulated by Nox4. [36] [37] [38] In this study, we observed increased TGFβ gene expression in the aorta of diabetic Nox1 and Nox4 WT mice ( Figure 5D and 5H). Deletion of Nox4 in diabetes mellitus resulted in a further significant elevation in TGFβ expression ( Figure 5D ), whereas Nox1 deletion did not change TGFβ expression ( Figure 5H ). Phosphorylated SMAD3 (p-SMAD3) and total SMAD3 (t-SMAD3) in the aorta were measured by Western blot analysis, to explore altered regulation of TGFβ signaling within the aortic tissue. Deletion of the NOX4 isoform resulted in a modest increase in p-SMAD3 compared with WT diabetic mice ( Figure VA in the online-only Data Supplement). In contrast, deletion of Nox1 resulted in a modest reduction in the level of p-SMAD3 when compared with WT diabetic mice ( Figure VB in the onlineonly Data Supplement). These results suggest that increased plaque formation in the diabetic Nox4-deficient mice was associated with increased deposition of lighter younger collagen fibers, including collagens I and III in the plaque body and the fibrous cap, whereas older and heavier collagens such as collagen IV were reduced. This seems to be mediated, at least in part, through a SMAD3-TGFβ-dependent mechanism.
In Arterial Endothelial Cells Knockdown of Nox4 Results in Lower H 2 O 2 Formation in Association With Enhanced Profibrotic Markers
HAECs had either Nox4 silenced in order to mimic the in vivo model of Nox4 deficiency or overexpressed to mimic an environment where there is enhanced ROS generated by Nox4. Cells were cultured under normal and high glucose conditions. Nox4 knockdown by shRNA demonstrated a 90% reduction in Nox4 mRNA levels ( Figure 6A ), whereas cells that were transfected to overexpress Nox4 demonstrated a 40% to 60% increase in Nox4 mRNA ( Figure 6A ). H 2 O 2 levels were significantly lower in Nox4 knockdown cells grown under high glucose ( Figure 6D ), and they were significantly increased in response to Nox4 overexpression ( Figure 6D ). Gene expression of the profibrotic marker, connective tissue growth factor (CTGF), was significantly increased in nontarget high glucose-cultured cells, which was further elevated in Nox4-silenced cells and attenuated in high glucose-cultured cells with Nox4 overexpression (Figure 6H ). These results indicated that under high glucose conditions, knockdown of Nox4 decreased endothelial H 2 O 2 production in association with an increase in the profibrotic marker CTGF. Furthermore, analysis of p-SMAD3 by Western blot identified that overexpression of Nox4 under high glucose conditions resulted in a significant reduction compared with Nox4-silenced cells under high glucose conditions ( Figure VI in the online-only Data Supplement). These results suggest that ROS derived from NOX4 can provide vascular protection through attenuation of proinflammatory and profibrotic mechanisms. These in vitro data replicate our in vivo findings and provide further mechanistic insight. Similar to our in vivo findings, we also found a counter-regulatory upregulation of Nox2 and p47phox when compared with cells grown under normal glucose conditions ( Figure 6E-6G) . In addition Rac-1 activity was increased, indicating augmented Nox2 activation in Nox4 shRNA cells grown under high glucose conditions ( Figure 6I ). This correlated with increased levels of nitrotyrosine staining, a possible biomarker for NOX2-derived superoxide interacting with NO. Thus, it is possible that some of the effects of NOX4 are mediated or reduced by NOX2 upregulation.
To test this further, Nox2 was silenced in Nox4 shRNA cells and cultured under normal and high glucose conditions using siRNA targeted to Nox2. Nox2 gene expression was significantly reduced by >50% in Nox2-silenced cells cultured under normal and high glucose conditions in both the nontarget and the Nox4 shRNA cells ( Figure 6J ). Examination of gene expression for MCP-1 and CTGF identified that silencing of Nox2 in Nox4 shRNA cells resulted in a significant reduction of these 2 proatherosclerotic markers when cultured under high glucose conditions ( Figure 6K and 6L). These results indicate that some of the effects of NOX4 are mediated through an upregulation of NOX2 activity. To clarify this further, future studies are needed using a double knockout mouse model and, currently not available, isoform-specific inhibitors.
Discussion
Here, we show for the first time that an enzymatic source of ROS, NOX4, can protect from atherosclerosis. Oxidative stress has been postulated to be a key mediator of endothelial dysfunction and vascular disease; however, all clinical therapies addressing this by the use of antioxidants have failed by being ineffective or even causing harm. 39 It is hypothesized that this is because of the fact that ROS do not have exclusively negative effects but also serve essential signaling functions, for example, in innate immunity, hormone synthesis, and angiogenesis. The key for therapeutic exploitation of ROS will thus be to differentiate between disease-triggering and physiological sources of ROS that should rather be left untouched. What may differentiate these 2 qualities can be quantity and type of ROS being formed (eg, H 2 O 2 as a signaling molecule versus superoxide as a reactive radical) as well as type of NOX isoforms.
NOX have emerged as the only known dedicated enzymatic source of ROS, that is, their only function is to produce ROS. All other sources of ROS (mitochondria, xanthine oxidase, and endothelial NO synthase) have other primary functions and need to be altered or damaged to generate ROS. Often this initial trigger is again ROS, so-called kindling radicals, for which NOX are a likely source. Our human gene expression data suggest that Nox4 deficiency is associated with plaque vulnerability possibly enhancing the risk of cardiovascular events particularly in the context of diabetes mellitus.
This protective role of NOX4 in the vasculature can be explained by anti-inflammatory and antiremodeling mechanisms. Interestingly, myocardial Nox4 expression is also reduced in patients with aortic valve stenosis suggesting that Nox4 deficiency maybe associated with myocardial and vascular remodeling. 40 Furthermore, deletion of Nox4 in a model of angiotensin II-induced vascular injury enhanced media hypertrophy and endothelial dysfunction 8 and in a model of cardiac hypertrophy induced cardiac hypertrophy via effects on angiogenesis and capillary density. 15 Targeted deletion of Nox4 in an angiotensin II-induced model of vascular injury resulted in a collapse of the antioxidant defense system, as reflected by changes in Nrf-2 and HO-1, contributing to enhanced NO bioavailability and hence reduced endothelial dysfunction. 8 In contrast, overexpression of Nox4 in endothelial cells resulted in an amplified response to acetylcholineand histamine-induced vasodilatation and a reduction in blood pressure 10 and was associated with increased recovery from hypoxia and increased angiogenesis. 9 Our studies using Nox4 −/− ApoE −/− mice are the first to demonstrate a protective role of Nox4 in diabetes mellitus-associated atherosclerosis. This model of streptozotocin-induced insulin-deficient diabetes melitus in ApoE −/− mice is currently, despite its possible limitations, the best available model and recommended by National Institutes of Health and Juvenile Diabetes Research Foundation to study advanced atherosclerosis in diabetes mellitus. 18 Increased plaque formation and remodeling as well as enhanced vascular inflammation in the absence of Nox4 in a model of long-term diabetes mellitus suggest a vasculoprotective role for Nox4 in atherosclerosis. These vasculoprotective effects of Nox4 include the formation of H 2 O 2 , downregulation of Nox2 and modulation of vascular macrophage accumulation and inflammation as well as Nox4-mediated effects on extracellular matrix remodeling. In contrast, NOX1 has deleterious effects on plaque formation in long-term atherosclerosis. Thus, our studies suggest that NOX1 and NOX4 represent an interesting example of 2 ROS sources having qualitatively opposing effects, deleterious, and protective within the same tissue and disease model. This may be related to the fact that NOX1 produces primarily superoxide and NOX4 H 2 O 2 or that both isoforms are located at different subcellular compartments.
The upregulation of functional Nox2 on the gene and protein level in vitro in HAECs and in vivo in the context of Nox4 silencing may represent another potential mechanism how the lack of NOX4 leads to increased atherosclerosis. Furthermore, NOX2 is not a valid target in the context of diabetes mellitus because diabetic Nox2 knockout mice showed increased mortality and infections. 3 Activation of inflammatory and profibrotic processes is critical in the promotion of atherosclerosis especially in diabetes mellitus. 3, 32, [41] [42] [43] [44] [45] Nox4 expression may also limit vascular inflammation and macrophage infiltration and thus lack of vascular Nox4 would presumably lead to increased activation of inflammatory pathways. In this study, we demonstrated not only increased circulating concentrations of MCP-1 but also increased aortic MCP-1 concentrations in diabetic Nox4 −/− ApoE −/− mice. MCP-1 is a mediator of chemotaxis of immune cells and in particular macrophages to the vascular wall. Indeed, there was increased macrophage accumulation within the aortic wall in diabetic WT mice, and this was further increased in diabetic Nox4-deficient mice. Previous studies have identified that deletion of Nox4 increases the survival of macrophages in atherosclerosis, albeit in a nondiabetic setting. 46 Our studies showing increased aortic MCP-1 protein and macrophage accumulation are consistent with the finding of enhanced macrophage recruitment and increased macrophage survival in the context of Nox4 deletion.
The later stages of atherosclerosis development are characterized by enhanced extracellular matrix deposition within plaques. Previous studies have suggested a role for Nox4 in TGFβ-mediated fibrosis with some studies suggesting a profibrotic effect of NOX4. 38 In needs to be considered that most of these studies investigated Nox4 in either kidney or pulmonary fibrosis and thus the effect of NOX4 may be site and organ specific. Our studies are the first to suggest an atheroprotective role for NOX4 in plaque remodeling in advanced atherosclerosis. We identified increased expression of newly formed fibrillar collagens such as collagens I and III in the plaque center and within the fibrous caps with a reduction in the older and 19, 47 and can be associated with smooth muscle cell transition from a contractile to a synthetic phenotype. 48 In contrast, collagen IV accumulation is associated with a more quiescent contractile phenotype of vascular smooth muscle cells. Collagens can act as an extracellular reservoir for cytokines and growth factors, including IL-1β, TGFβ, CTGF, and TNFα. [49] [50] [51] In this study, we identified increased expression of IL-1β, TGFβ, and TNFα in the aorta of diabetic Nox4 −/− ApoE −/− mice. It has been demonstrated that TGFβ promotes collagen production through SMAD3 binding and increased production of CTGF. 50, [52] [53] [54] In a rat model of balloon injury model, TGFβ induced overproduction of collagens, resulting in stiffer arteries. 50 Consistent with these findings, we identified increases in TGFβ expression at the gene level in the diabetic Nox4 −/− ApoE −/− mice, supportive of a profibrotic environment within the plaques. SMAD signaling has been suggested to play a key role in the promotion of fibrosis within the vascular system. 36, 55 Furthermore, other studies have shown that under high glucose conditions there is enhanced translocation of SMAD3 to the nucleus, 56 contributing to enhanced expression of fibrotic markers. Here, we show a modest increase in activated SMAD3 in the aorta of diabetic Nox4 −/− ApoE −/− mice compared with WT mice, consistent with the enhanced fibrotic environment within the atherosclerotic plaques. In vitro, we have confirmed that Nox4 deficiency in human aortic endothelial cells exposed to high glucose demonstrate reduced H 2 O 2 , with increased upregulation of the profibrotic growth factor, CTGF, in association with increased pSMAD3 signaling. Cosilencing of both Nox2 and Nox4 suggests that some of these proinflammatory and profibrotic changes observed with Nox4 deletion are mediated, at least in part, via Nox2 activation. NOX2 activation in endothelial cells is associated with increased expression of MCP-1 leading to further vascular immune-cell recruitment. Furthermore, these changes are associated with increased expression of profibrotic growth factors and increased SMAD3 signaling, leading to plaque remodeling. These changes observed with Nox4 deletion were rescued by Nox4 overexpression. These studies demonstrate an important atheroprotective role for Nox4 in endothelial cells. However, we cannot exclude a role for NOX4 in cells other than endothelial cells of the vasculature, which needs further investigation.
In conclusion, this is the first study to demonstrate an atheroprotective role of a specific form of ROS, H 2 O 2 and its enzymatic source, Nox4, in advanced atherosclerosis development modulating inflammation and plaque remodeling. Furthermore, these results suggest that isoform-specific inhibitors are advisable when aiming at exploiting NOX for chronic therapeutic intervention. As such, this is an important example for redefining the roles of ROS in physiology and disease. [1] [2] [3] . Only animals with a blood sugar level >15 mmol/l 1 week after induction of diabetes were included in the study. At 19 weeks post induction of diabetes systolic blood pressure was assessed by non-invasive tail cuff system in conscious mice 4 . After 20 weeks, the animals were anaesthetised by i.p. injections of sodium Pentobarbitone (100mg/kg body weight; Euthatal, Sigma-Aldrich, Castle Hill, NSW, Australia). Glycated haemoglobin (HbA1c) was measured in erythrocyte lysates by HPLC (Bio-Rad, USA). Total glucose, cholesterol and triglyceride concentration were measured in plasma with a standard commercial enzymatic assay (Beckman Coulter Diagnostics, Gladsville, NSW, Australia). Organs were rapidly dissected and weights obtained before being either snap frozen in liquid nitrogen or fixed in buffered formalin (10%v/v).
Atherosclerotic Plaque Area Quantification: Assessment of plaque area was undertaken using en face analysis. Aorta removed from all animals were cleaned and stained with Sudan IV-Herxheimer's solution (BDH, Poole UK) as previously described 5 . Digitised photographs of opened aorta were obtained using a dissecting microscope (Olympus SZX9; Olympus Optical, Tokyo, Japan) and a digital camera set up (Axiocam Colour Camera; Carl Zeiss, North Ryde, NSW, Australia). Plaque area was calculated as the proportion of aortic intimal surface area occupied by red-stained plaque (Adobe Photoshop v6.0.1; Adobe Systems, Chatswood, NSW, Australia).
Human Microarray: Total RNA was extracted from carotidartery sections obtained from surgery (Department of Surgery, Maasland Hospital Sittard, Sittard, the Netherlands). Lesions were sectioned and alternate sections were examined for progression stage according to Virmani 6 . RNA was isolated using the Guanidine Thiocyanate (GTC)/CsCl gradient method and a NucleoSpin RNA II kit (Macherey-Nagel GmbH & Co. KG). Samples were individually hybridized to Illumina Human Sentrix-8 V2.0 BeadChip® (Illumina Inc., San Diego, USA, California). Preprocessing was performed with affy using the Robust MultiArray (RMA) normalization 7, 8 . Empirical Bayesian shrinkage of the standard errors have been used to moderate t-statistics, F-statistics, and log-odds of differential expression. The resulting ordered dataset has been queried for the set of genes of interest and their results are hereby presented. The adjusted p-values presented in the results are corrected according to the Benjamini and Hochberg False Detection Rate method.
Quantitative RT-PCR: Total aortic RNA was extracted after homogenisation (Polytron PT-MR2100; Kinematica, Littau/Lucerne, Switzerland) in TRIzol reagent (Invitrogen Australia, Mt Waverly, Vic, Australia). Contaminating DNA was removed after treatment with DNA-free DNAse according to the manufacturer's specifications (Ambion, Austin, TX, USA). Finally, DNA-free RNA was reverse transcribed into cDNA using the Superscript First Strand Synthesis System (life Technologies BRL, Grand Island, NY, USA). Expression of gene encoding members of the NADPH oxidase family, Nox1, Nox2, Nox4, p47phox, SOD, Gpx1, Catalase, CTGF, TGFβ, TNFα, IL-1β, Collagen I, III and IVα3 were analysed by quantitative RT-PCR using Taqman system (ABI Prism 7500; Perkin-Elmer, Poster City, CA, USA). Primer and probes sequences have been published previously [9] [10] [11] [12] [13] . Fluorescence for each cycle was analysed quantitatively and gene expression normalised relative to the expression of the housekeeping gene 18S rRNA (18S ribosomal RNA Taqman Control Reagent Kit), which was multiplexed together with the gene of interest. Probes and primers were designed using a Primer Express program and were purchased from Applied Biosystems (ABI, Foster City, CA, USA). Results were expressed relative to Non-diabetic ApoE -/-mice, which were arbitrarily assigned a value of 1 3 .
Histological Stains, Immunohistochemistry and Immunofluroesence: Paraffin sections (4µM) of aorta were used for histological stains for collagen deposition using Masson's Tirchome and Picro-Sirius Red as previously described 9, 14 . Immunohistochemistry stains were performed on paraffin sections (4µm) of aorta for nitrotyrosine (rabbit polyclonal; Millipore, Billercia, MA, USA; 1:100), F4/80 (rat monoclonal; Abcam, Cambridge, AM, USA; 1:100) and Nox2 (rabbit monoclonal; Abcam, Cambridge, AM, USA; 1:250) as previously described 3, 15, 16 . In brief, sections were dewaxed, hydrated and quenched in 3% H 2 O 2 in TRIS-buffered saline (pH 7.6) to inhibit endogenous peroxidise activity. Sections were incubated with Protein Blocking Agent (Thermo Electron, Pittsburgh, PA, USA) for 60 minutes at room temperature, then in primary antibody overnight at 4 o C in a humidified chamber. Sections were incubated in the appropriate biotinylated secondary antibody (All from Vector Laboratories), followed by horseradish peroxidise-conjugated streptavidin (Vectastain Elite ABC Staining Kit; Vector Laboratories). Staining was amplified further by Dako Catalysed Signal Amplification Kit, according to instructions (Dako Cytomation). All signals were visualised with 3,3'-diamino-benzidine terahydrochloride/H 2 O 2 (DAB; SigmaAldrich, St Louis, MO, USA). Finally, sections were counterstained with Mayer's haematoxylin, dehydrated and coverslipped. All sections were examined under light microscope (Olympus BX-50; Olympus Optical) and digitised with a high resolution camera. All digital quantification (image-Pro Plus; v6.0) and assessments were performed in a blinded manner. Results were expressed relative to non-diabetic ApoE -/-mice, which were arbitrarily assigned a value of 1 3 . HAEC cells grown on cover slipsin a 24 well plate with and without glucose for 48 hours. Cells were fixed in 4% PFA for 15 minutes before being repeatedly washed in TBS. Cells were incubated with primary antibody Nox2 (rabbit polyclonal, Abcam, Cambridge AM, USA; 1:100) at 4 o C overnight. Cells were washed with TBS to remove the primary antibody before being incubated with Alexa 488 secondary antibody (Abcam, Cambridge, AM, USA; 1:500) for 2 hours at room temperature. Cells were mounted onto slides using PorLong Gold Antifade reagent with DAPI (Molecular Probes, USA) and left at 4oC until set. Images were obtained using a confocal microscope (Monash MicroImaging, Monash University, Australia).
Measurement of Superoxide production in Aortic Sections:
Aortic superoxide generation was evaluated in frozen aortic sections with the oxidative fluorescent dye dihydroethidium (DHE) as described previously 17 . Briefly, cryosections (6µm) were incubated with 2µmol/L Dihydroethidium (DHE; Molecular Probes, Eugene, OR USA) in DMSO, at room temperature for 1 hour. Sections were rinsed quickly with PBS and mounted in AquaMount media for imaging (Olympus BX61, Olympus Optical, Japan). The excitation wavelength was 488nm and the emission fluorescence was detected by a 590nm long-pass filter. Images were taken at a low exposure time to minimize any background fluorescence. Fluorescent ethidium signal was quantified using NIH Image J software and expressed as the mean fluorescence intensity of the whole aorta.
Measurement of Hydrogen Peroxide Production in Aortic Tissue:
Hydrogen peroxide generation was measured in 10-15mm segments of aortas by Amplex Red using a commercial kit following manufacturer's instructions (Molecular Probes, Eugene, OR, USA) 3 . In short, cytosolic and mitochondrial extractions were prepared as previously described 18 .
Twenty microliters of each fraction, standard and blank were assayed in duplicates in a black 96-well plate after addition of pre-warmed (37 o C) working solution containing 100µM Amplex Red reagent and 0.2U/ml horseradish peroxidase. Fluorescence intensity was measured on a fluorescence microplate reader after 30 minutes at excitation of 544nm and emission of 590nm at 37 o C. Aortic MCP-1, TNFα and IL-1β ELISA: Aortic MCP-1, TNFα and IL-1β were measured in whole protein preparations as described previously 19 and measured using commercial kit's following manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Measurement of Superoxide
Western Blot: Western blots of total aortic protein were performed as previously described 13, 20 . In brief, protein was extracted from aortas and were subjected to 10-12% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The membranes were incubated with antibodies targeted to t-SMAD3 (rabbit monoclonal; OriGene, USA, 1:500) and p-SMAD3 (rabbit monoclonal; Abcam, AM, USA, 1:250. The membranes were washed with Tris-buffered saline with Tween and then incubated with fluorescently labelled secondary antibodies and visualised using the Odyssey® Infrared Imaging Systems (Li-Cor Biosciences, Lincoln, NE, USA).
Cell Culture Experiments:
Human aortic endothelial cells (HAECs) were obtained from Clonetics (Lonza, USA) and grown into 75cm 2 culture flasks (250,000 per flask with humidified incubator, 5% CO 2 ) at 37°C in the presence of EGM-2 Bulletkit supplemented with endothelial growth media. HAECs were used between passages six and eleven. EGM-2 containing 25mmol/l glucose (Sigma Chemical, St Louis, MO, USA) was used as a high glucose condition in all the experiments, while regular EGM-2, which contains 5.6mmol/l glucose, was used as the normal glucose condition. 25mM mannitol was used as an osmotic control. In all experiments, HAECs were used at 80% to 90% confluence. On the day of the experiment, cells were washed with PBS, trypsinized and re-suspended in fresh EGM-2. 30,000 cells per ml were then plated into 6-well plates and incubated for 24 hours. The cells were then harvested for isolation of mRNA and gene expression analyses (RT-PCR), which were carried out as outlined above.
shRNA knockdown and Over-Expression of Nox4 in vitro: The knockdown of Nox4 was performed using HAECs by MISSION shRNA expressing lentivirus vectors (Sigma) as described previously 21 . The sequence for Nox4 TRC0000046092, 5'GAGCCTCAGCATCTGTTCTTA3' in addition to a non-target control 5'CAACAAGATGAAGAGCACCAA3'. shRNA lentivirus particles ware produced in 293FT cells by co-transfection with ViraPower Lentiviral Packaging Mix (Invitrogen, Molecular Probes, USA). The cells transduced with the MISSION Non-target shRNA control vector particles (Sigma-Aldrich, St Louis, MO, USA) were used as controls. HAECs were seeded at 1 x10 6 cells/dish in a 100mm dish and infected by the lentivirus particles in the presence of 8μg/ml polybrene for 2 days, followed by selection in puromycin (1µg/ml; Sigma-Aldrich, St Louis, MO, USA) for 5 days. The knockdown efficiency in the cells was verified by qRT-PCR and was greater than 90% for Nox4. Nox4 over-expression was performed as previously described 22 . Briefly, human Nox4 was sub-cloned into a pBabe retroviral vector. Phoenix cells were transfected with pBabe-Nox4 or pBabe-MCS. Filtered supernatant containing retroviral particles was added to HAEC cells in the presence of Hexadimethrine bromide (10ug/mL). Successfully infected cells were selected with puromycin (0.6ug/mL).
Knockdown of Nox2 in vitro
The knockdown of Nox2 was performed in HAECs using Lipofectamine RNAiMAX reagent with either scramble siRNA or siRNA targeted to Nox2 (NM_000397.3). Knockdown efficiency was verified by RT-PCR and was greater than 50% for Nox2. HAECs were seeded at 10,000 cells/6-well dish. The following day cells were cultured in Opti-MEM Media (Life Technologies) for 30mins at which point cells were incubated with lipofectamine RNAiMAX reagent (0.2ul/well; Life Technologies, Carlsbad, CA) with either non-target scramble control (Ambion, USA) or siRNA against Nox2 (Ambion, USA) for 4 hours. After 4 hours, fresh 10% FBS supplement Opti-MEM Media was added and treatment with glucose commenced. Cells were incubated for 24 hours at which point they were harvested for RNA extraction and RT-PCR.
Measurement of ROS in vitro:
ROS was measured in HAEC cells (+/-glucose) using Amplex Red and L-012 as previously described Statistical Analysis: Data were analysed for normality using the Shipiro-Wilk test before being analysed with either a 1-Way ANOVA or a 2-Way ANOVA using SPSS Statistics version 20 (IBM) with an LSD post-hoc test for multiple comparisons of the means, P<0.05 was considered statistically significant. All results are mean±SEM, unless otherwise specified. 
